2025
Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series
Vierra M, Morgan R, Ostowari A, Turaga K, Shergill A, Eng O. Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series. Journal Of Gastrointestinal Oncology 2025, 16: 757-765. PMCID: PMC12078827, DOI: 10.21037/jgo-24-440.Peer-Reviewed Original ResearchLow-grade appendiceal mucinous neoplasmProgression-free survivalSystemic chemotherapyAppendiceal mucinous neoplasmPseudomyxoma peritoneiCase seriesCarcinoembryonic antigenMucinous neoplasmsFolinic acidAnti-vascular endothelial growth factorMedian progression-free survivalCEA responseMetastatic peritoneal diseaseElevated carcinoembryonic antigenPeritoneal cancer indexMedian follow-upBenefit of chemotherapyResponse to chemotherapyCycles of chemotherapyOutcomes of patientsTreated 5 patientsUniversity of Chicago Medical CenterEndothelial growth factorUnresectable diseasePeritoneal diseaseCabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
Ebrahimi H, Meza L, Dizman N, Barragan-Carrillo R, Li X, Llamas-Quitiquit M, Hsu J, Zengin Z, Castro D, Mercier B, Zugman M, Jaime-Casas S, Chehrazi-Raffle A, Trent J, Lee P, Takahashi M, Dorff T, Caporaso G, Lee K, Pal S. Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study. Journal Of Clinical Oncology 2025, 43: 543-543. DOI: 10.1200/jco.2025.43.5_suppl.543.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsClinical benefitControl armTreatment armsFollow-upImproving progression-free survivalMedian progression-free survivalMetastatic renal cell carcinomaTime of data cutoffTarget lesion sizeTreatment naive patientsMedian follow-upPhase I studyKaplan-Meier methodSecondary clinical endpointsRenal cell carcinomaKarnofsky performance statusFisher's exact testMedian OSSarcomatoid featuresStable diseaseComplete responseData cutoffPapillary histologyDatopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
Meric-Bernstam F, Alhalabi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira A, Salkeni M, Gao X, Tolcher A, Bhave M, Doroshow D, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Journal Of Clinical Oncology 2025, 43: 663-663. DOI: 10.1200/jco.2025.43.5_suppl.663.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsBlinded independent central reviewProgression-free survivalDuration of responsePartial responseIndependent central reviewComplete responseConfirmed ORRUrothelial cancerCentral reviewMedian duration of responseMedian progression-free survivalResponse rateImmune checkpoint inhibitorsInterstitial lung disease/pneumonitisTreatment-related AEsMedian follow-upSolid tumor typesAntibody-drug conjugatesPrimary study objectiveCheckpoint inhibitorsDose interruptionPretreated ptsStable diseaseData cutoffAssociation between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.
Mohanna R, Simsek B, El Ahmar N, Jegede O, Matar S, Paul M, Nabil Laimon Y, Roberti De Oliveira G, Delcea A, Choueiri T, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial. Journal Of Clinical Oncology 2025, 43: 590-590. DOI: 10.1200/jco.2025.43.5_suppl.590.Peer-Reviewed Original ResearchAdvanced clear cell renal cell carcinomaClear cell renal cell carcinomaProgression-free survivalPD-1 expressionTumor-infiltrating TregsCell renal cell carcinomaRegulatory T cellsPD-1Renal cell carcinomaClinical trialsCell carcinomaT cellsEfficacy of PD-1 blockadeInhibition of PD-1 signalingLevel of PD-1 expressionShorter median progression-free survivalTumor-infiltrating regulatory T cellsAssociated with progression-free survivalMedian progression-free survivalPercentage of PD-1First-line nivolumabFirst-line settingPD-1 blockadePD-1 signalingLog-rank testA phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
Sadeghi S, Callis S, Lara P, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian Murchie Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2025, 43: tps887-tps887. DOI: 10.1200/jco.2025.43.5_suppl.tps887.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaProgression-free survivalStandard of careEnfortumab vedotinOverall survivalCisplatin-ineligible metastatic urothelial carcinomaMedian progression-free survivalPhase III randomized trialStudies of eribulinMedian overall survivalPlatinum-based chemotherapyLines of therapyEndpoint of OSOne-sided alphaFGFR3 alterationsLiver metastasesSystemic therapyEligible ptsUrothelial carcinomaPrimary endpointSecondary endpointsGenitourinary cancersEribulinTreatment changesGemcitabineOlaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Cecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso P. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025, 131: e35755. PMID: 39917990, DOI: 10.1002/cncr.35755.Peer-Reviewed Original ResearchConceptsProgression-free survivalHomologous recombination deficiencyClinical benefitNational Cancer InstituteIDH inhibitorsMedian progression-free survivalAccumulation of 2-hydroxyglutaratePhase 2 clinical trialIsocitrate dehydrogenase inhibitorsMedian overall survivalSingle-agent activityNovel combination therapiesEnhance patient selectionSubgroup of patientsOverall survivalOpen-labelCombination therapyIDH mutationsPatient selectionRecombination deficiencySolid tumorsTumor progressionClinical trialsOlaparibCholangiocarcinomaCiltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat R, Oriol A, Cavo M, Karlin L, Avivi I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Transplantation And Cellular Therapy 2025, 31: s35. DOI: 10.1016/j.jtct.2025.01.047.Peer-Reviewed Original ResearchMinimal residual disease negativityMRD-negativity ratesMinimal residual diseaseProgression-free survivalCilta-cel infusionSustained MRD negativityCilta-celMRD negativityOverall survivalMultiple myelomaSOC armMinimal residual disease positivityMedian progression-free survivalInterim analysisStandard of careMedian OSComplete responseMRD evaluationResidual diseaseCiltacabtagene autoleucelBridging therapyPost-infusionNext-generation sequencingTherapyInfusionTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry A, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel A, Finn R, Llovet J, investigators L. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet 2025, 405: 203-215. PMID: 39798578, DOI: 10.1016/s0140-6736(24)02575-3.Peer-Reviewed Original ResearchConceptsEastern Cooperative Oncology GroupNon-metastatic hepatocellular carcinomaProgression-free survivalTreatment-related adverse eventsPembrolizumab groupPhase 3 studyTransarterial chemoembolisationPlacebo groupHepatocellular carcinomaIntention-to-treatOverall survivalDouble-blindPerformance statusAdverse eventsFollow-upEastern Cooperative Oncology Group performance statusChild-Pugh class A diseaseMedian progression-free survivalSolid Tumors version 1.1Blinded independent central reviewA-fetoprotein levelAlbumin-bilirubin gradeResponse Evaluation CriteriaAs-treated populationMedian follow-upFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatment
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, 43: 536-544. PMID: 39671534, PMCID: PMC11798714, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabinePhase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman R, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd G, Harris L, Isaacs C, Dees C, Perou C, Johnson G, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover D, Ramaswamy B. Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Research And Treatment 2024, 210: 179-189. PMID: 39644403, DOI: 10.1007/s10549-024-07551-z.Peer-Reviewed Original ResearchMetastatic triple negative breast cancerProgression-free survivalCirculating tumor DNATriple negative breast cancerTrametinib monotherapyNegative breast cancerStable diseasePartial responseBreast cancerCirculating tumor DNA clearanceMedian progression-free survivalClinical benefit rateMEK inhibitor trametinibPhase II studyBiomarkers of responseTreated with chemotherapyPotential early biomarkersInhibitor trametinibOpen-labelOverall survivalConclusionIn patientsDevelopment of resistanceObjective responseTumor DNABenefit rateCiltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat R, Oriol A, Cavo M, Karlin L, Mazza I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Blood 2024, 144: 1032. DOI: 10.1182/blood-2024-201533.Peer-Reviewed Original ResearchMinimal residual disease negativityMRD-negativity ratesSustained MRD negativityMinimal residual diseaseProgression-free survivalMedian progression-free survivalCilta-celMRD negativitySOC armOverall survivalMultiple myelomaInterim analysisPost-infusionFollow-upMinimal residual disease assessmentMinimal residual disease dataMinimal residual disease positivityCilta-cel infusionProlonged survival outcomesMedian follow-upOverall response rateNegative resultsStandard of careMedian OSComplete responsePhase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, García-Sancho A, Advani R, Vidal J, de Oña Navarrete R, Marin-Niebla A, Izquierdo A, Terol M, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances 2024, 8: 4581-4592. PMID: 38991123, PMCID: PMC11401221, DOI: 10.1182/bloodadvances.2024012806.Peer-Reviewed Original ResearchRelapsed/refractory peripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaT-cell lymphomaProgression-free survivalDuration of responseAdverse eventsAngioimmunoblastic T-cell lymphoma patientsMedian duration of responseMedian progression-free survivalSafety of tipifarnibHematologic adverse eventsMedian overall survivalTreatment-related deathsBiomarkers of responsePhase 2 trialSixty-five patientsFarnesyltransferase inhibitor tipifarnibNon-responder groupTumor mutational profileSingle-arm trialPTCL-NOSOpen-labelOverall survivalPrimary endpointTROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
Petrylak D, Tagawa S, Jain R, Bupathi M, Balar A, Kalebasty A, George S, Palmbos P, Nordquist L, Davis N, Ramamurthy C, Sternberg C, Loriot Y, Agarwal N, Park C, Tonelli J, Vance M, Zhou H, Grivas P, Petrylak D, Tagawa S, Jain R, Bupathi M, Balar A, Kalebasty A, George S, Palmbos P, Nordquist L, Davis N, Ramamurthy C, Sternberg C, Agarwal N, Park C, Tonelli J, Vance M, Zhou H, Grivas P, Loriot Y. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. Journal Of Clinical Oncology 2024, 42: 3410-3420. PMID: 39186707, PMCID: PMC11458109, DOI: 10.1200/jco.23.01720.Peer-Reviewed Original ResearchConceptsMetastatic urothelial cancerClinical benefit rateProgression-free survivalDuration of responseCisplatin-ineligible patientsCheckpoint inhibitor therapyPhase II studyCheckpoint inhibitorsSacituzumab govitecanCohort 2Central reviewOpen-label phase II studyPlatinum (Pt)-based chemotherapyMedian duration of responseMedian progression-free survivalTreatment-emergent adverse eventsMedian overall survivalSN-38 payloadUrothelial cancer progressionSecondary end pointsAntibody-drug conjugatesCisplatin-ineligibleInhibitor therapyOverall survivalII studyReal-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
Lee C, Yoo C, Hong J, Park J, Kim J, Tai D, Kim H, Korphaisarn K, Tanasanvimon S, Chen S, Kim J, Kim I, Kim M, Choo J, Oh S, Chen C, Bae W, Kim H, Huh S, Yen C, Park S, Lee D, Chan L, Kang B, Kang M, Sundar R, Choi H, Chan S, Chon H, Lee M. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries. Liver Cancer 2024, 1-15. DOI: 10.1159/000540969.Peer-Reviewed Original ResearchFirst-line atezolizumabProgression-free survivalImmune checkpoint inhibitorsTyrosine kinase inhibitorsSecond-line regimensOverall survivalHepatocellular carcinomaSecond-line progression-free survivalSecond-line tyrosine kinase inhibitorsPatients treated with tyrosine kinase inhibitorsAssociated with improved OSImmune checkpoint inhibitor combinationsImmune checkpoint inhibitor useMedian progression-free survivalLow tumor burdenAdvanced hepatocellular carcinomaFirst-line regimenReal-world studyCheckpoint inhibitorsTumor burdenSystemic treatmentAtezolizumabBevacizumabRetrospective studyLenvatinibPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXEfficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Santin A, Corr B, Spira A, Willmott L, Butrynski J, Tse K, Patel J, Mekan S, Wu T, Lin K, Kuo P, Dumbrava E. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. Journal Of Clinical Oncology 2024, 42: 3421-3429. PMID: 39083724, PMCID: PMC11458108, DOI: 10.1200/jco.23.02767.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseTreatment-related adverse eventsAdvanced endometrial cancerEndometrial cancerSacituzumab govitecanTrop-2Investigator assessmentSolid tumorsTrophoblast cell surface antigen 2Median duration of responsePhase II basket studyMedian progression-free survivalEnd pointsBaseline tumor specimensClinical benefit ratePlatinum-based therapyStudy drug discontinuationAdvanced solid tumorsMedian follow-upMetastatic solid tumorsTrop-2 expressionSecondary end pointsPrimary end pointEfficacy of SGA phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
Sanoff H, Deal A, Patel J, Sorah J, Gaddy J, O’Neil B, Turk A, Irvin W, Boles J, Lee M, McRee A, Wardell A, Weck K, Basch E, Wood W, Innocenti F. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The Oncologist 2024, 29: 786-793. PMID: 38837045, PMCID: PMC11379652, DOI: 10.1093/oncolo/oyae122.Peer-Reviewed Original ResearchProgression-free survivalMetastatic colorectal cancerOverall survivalIrinotecan doseColorectal cancerMedian progression-free survivalMetastatic colorectal cancer patientsEstimates of overall survivalFirst-line settingUnresectable colorectal cancerRates of neutropeniaFirst-line therapyPhase II trialPatient-reported adverse eventsRate of diarrheaG3/4 toxicitiesUGT1A1 genotypeIrinotecan metabolismFirst-linePrimary endpointSecondary endpointsAdverse eventsFOLFIRIHistorical controlsNon-genotypeSACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Garrido-Castro A, Kim S, Desrosiers J, Nanda R, Carey L, Clark A, Sacks R, O'Connor T, Sinclair N, Lo K, Thomas A, Wrabel E, O'Meara T, Lin N, Burstein H, He M, Rimm D, Mittendorf E, Tayob N, Tolaney S. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. Journal Of Clinical Oncology 2024, 42: lba1004-lba1004. DOI: 10.1200/jco.2024.42.17_suppl.lba1004.Peer-Reviewed Original ResearchProgression-free survivalMetastatic breast cancerHR+/HER2- metastatic breast cancerPD-L1 expressionSacituzumab govitecanAntibody drug conjugatesOverall survivalArm BPD-L1Arm ASN-38Study therapyBreast cancerHormone receptor-positive/HER2-negative breast cancerOpen-label phase 2 studyFollow-upDeplete regulatory T cellsFrequent treatment-related toxicitiesHormone receptor-positive/HER2-negativeImproving progression-free survivalTopoisomerase I inhibitor payloadMedian progression-free survivalRandomized phase II trialUpregulated MHC class IT cell effector function[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh D, Yoo C, Halfdanarson T, Falk S, Folitar I, Zhang Y, Aimone P, de Herder W, Ferone D, Investigators A. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet 2024, 403: 2807-2817. PMID: 38851203, DOI: 10.1016/s0140-6736(24)00701-3.Peer-Reviewed Original ResearchGastroenteropancreatic neuroendocrine tumorsProgression-free survivalAdvanced gastroenteropancreatic neuroendocrine tumorsLong-acting octreotideLu-DOTATATENeuroendocrine tumorsGrade 2Open-labelControl groupTreated patientsWell-differentiatedStandard first-line treatment optionMedian progression-free survivalProgression-free survival eventsTreatment periodFirst-line treatment optionProgression-free survival analysisNeuroendocrine tumor gradingSomatostatin receptor-positiveFirst-line therapyInteractive response technologyHigh-dose octreotidePhase 3 studyPhase 3 trialStandard of care
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply